University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Arun P. Wiita, MD, PhD

Arun P. Wiita, MD, PhD

Health Sciences Clinical Instructor, Dept. of Laboratory Medicine, UCSF

Cancer Center Program Memberships

Hematopoietic Malignancies

Research Summary

My research laboratory spans a number of areas within genomics, proteomics, and hematologic malignancies. One major area of research involves the use of targeted, quantitative proteomics to answer important biological questions in myeloma and B-cell leukemia. We are particularly interested in questions related to translational regulation after cancer therapy as well as how clinically-relevant genomic alterations result in phenotypic changes at the level of the proteome. Furthermore, my group includes the UCSF Stephen and Nancy Grand Multiple Myeloma Translational Initiative Laboratory. In this role, we collaborate with industry and academic partners to advance preclinical evaluation of novel myeloma therapeutics using a suite of in vitro and in vivo approaches.

In my clinical work, I am Assistant Director of the UCSF Clinical Cytogenetics laboratory. In this role, I interpret molecular genetic testing for the prenatal and postnatal diagnosis of microdeletion and microduplication syndromes. In this area we have translational interests in emerging technologies for determination of DNA copy number variation, integration of single-nucleotide variants and CNV interpretation, and cell-free DNA for prenatal testing. In my research laboratory we are also using quantitative proteomics to evaluate the role of protein homeostasis in determining the phenotypic effects of CNVs, as well using CRISPR/Cas9 genome engineering to generate new functional models of syndromic CNVs.

Education

2002, Princeton University, Princeton, NJ, A.B., Chemistry
2008, Columbia University, New York, NY, Ph.D, Neurobiology/Biophysics
2009, Columbia University, New York, NY, M.D., Medicine
2012, University of California, San Francisco, CA, Residency, Laboratory Medicine
2014, University of California, San Francisco, CA, Post-Doc, Pharmaceutical Chemistry


Professional Experience

  • 2007
    Graduate Student Fellow, Columbia U. Science & Technology Venture
  • 2008-2009
    Co-founder, MedVolution Systems, Inc. (clinical decision support software)
  • 2009-2012
    Resident, Dept. of Laboratory Medicine, UCSF
  • 2012-2014
    Post-doctoral Scholar, Wells Lab, Dept. of Pharmaceutical Chemistry, UCSF
  • 2014-present
    HS Clinical Instructor, Dept. of Laboratory Medicine, UCSF

Honors & Awards

  • 2008
    Winner, Wharton Venture Award, team “Bayesian Diagnosis Pro”, U. Penn.
  • 2008
    Dean’s Award for Excellence in Research, Columbia U. College of P&S (best Ph.D. thesis prize)
  • 2010, 2013
    Paul Strandjord Young Investigator Award, Academy of Clinical & Lab. Physicians and Scientists
  • 2010
    Laurence J. Marton Award for Excellence in Research, Dept. Lab. Med., UCSF
  • 2010
    Julius Krevans Award for Clinical Excellence, San Francisco General Hospital/UCSF
  • 2012
    NIH Ruth F. Kirschstein F32 Post-doctoral Fellowship (declined)
  • 2012
    Jane Coffin Childs Fund Post-doctoral Fellowship (declined)
  • 2012-15
    Damon Runyon Cancer Research Foundation Post-doctoral Fellowship

Selected Publications

  1. Crottès D, Lin YT, Peters CJ, Gilchrist JM, Wiita AP, Jan YN, Jan LY. TMEM16A controls EGF-induced calcium signaling implicated in pancreatic cancer prognosis. Proc Natl Acad Sci U S A. 2019 Jun 25; 116(26):13026-13035.
    View on PubMed
  2. Trinklein ND, Pham D, Schellenberger U, Buelow B, Boudreau A, Choudhry P, Clarke SC, Dang K, Harris KE, Iyer S, Jorgensen B, Pratap PP, Rangaswamy US, Ugamraj HS, Vafa O, Wiita AP, van Schooten W, Buelow R, Force Aldred S. Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies. MAbs. 2019 Feb 20; 1-14.
    View on PubMed
  3. Spector JD, Wiita AP. ClinTAD: a tool for copy number variant interpretation in the context of topologically associated domains. J Hum Genet. 2019 May; 64(5):437-443.
    View on PubMed
  4. Abrahams CL, Li X, Embry M, Yu A, Krimm S, Krueger S, Greenland NY, Wen KW, Jones C, DeAlmeida V, Solis WA, Matheny S, Kline T, Yam AY, Stafford R, Wiita AP, Hallam T, Lupher M, Molina A. Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001. Oncotarget. 2018 Dec 28; 9(102):37700-37714.
    View on PubMed
  5. Choudhry P, Galligan D, Wiita AP. Seeking Convergence and Cure with New Myeloma Therapies. Trends Cancer. 2018 08; 4(8):567-582.
    View on PubMed
  6. Lam C, Ferguson ID, Mariano MC, Lin YT, Murnane M, Liu H, Smith GA, Wong SW, Taunton J, Liu JO, Mitsiades CS, Hann BC, Aftab BT, Wiita AP. Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica. 2018 Jul; 103(7):1218-1228.
    View on PubMed
  7. Goode B, Mondal G, Hyun M, Ruiz DG, Lin YH, Van Ziffle J, Joseph NM, Onodera C, Talevich E, Grenert JP, Hewedi IH, Snuderl M, Brat DJ, Kleinschmidt-DeMasters BK, Rodriguez FJ, Louis DN, Yong WH, Lopes MB, Rosenblum MK, Butowski N, Tihan T, Bollen AW, Phillips JJ, Wiita AP, Yeh I, Jacobson MP, Bastian BC, Perry A, Solomon DA. A recurrent kinase domain mutation in PRKCA defines chordoid glioma of the third ventricle. Nat Commun. 2018 02 23; 9(1):810.
    View on PubMed
  8. Deshpande A, Yadav S, Dao DQ, Wu ZY, Hokanson KC, Cahill MK, Wiita AP, Jan YN, Ullian EM, Weiss LA. Cellular Phenotypes in Human iPSC-Derived Neurons from a Genetic Model of Autism Spectrum Disorder. Cell Rep. 2017 Dec 05; 21(10):2678-2687.
    View on PubMed
  9. Le Moigne R, Aftab BT, Djakovic S, Dhimolea E, Valle E, Murnane M, King EM, Soriano F, Menon MK, Wu ZY, Wong ST, Lee GJ, Yao B, Wiita AP, Lam C, Rice J, Wang J, Chesi M, Bergsagel PL, Kraus M, Driessen C, Kiss von Soly S, Yakes FM, Wustrow D, Shawver L, Zhou HJ, Martin TG, Wolf JL, Mitsiades CS, Anderson DJ, Rolfe M. The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma. Mol Cancer Ther. 2017 11; 16(11):2375-2386.
    View on PubMed
  10. Liu TY, Huang HH, Wheeler D, Xu Y, Wells JA, Song YS, Wiita AP. Time-Resolved Proteomics Extends Ribosome Profiling-Based Measurements of Protein Synthesis Dynamics. Cell Syst. 2017 Jun 28; 4(6):636-644.e9.
    View on PubMed
  11. Qi Z, Madaan S, Chetty S, Yu J, Wiita AP. False negative fetal cell free DNA screening for microdeletion syndromes in the presence of an unbalanced translocation involving monosomy 4p. Prenat Diagn. 2017 04; 37(4):420-422.
    View on PubMed
  12. Sherbenou DW, Aftab BT, Su Y, Behrens CR, Wiita A, Logan AC, Acosta-Alvear D, Hann BC, Walter P, Shuman MA, Wu X, Atkinson JP, Wolf JL, Martin TG, Liu B. Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. J Clin Invest. 2016 12 01; 126(12):4640-4653.
    View on PubMed
  13. Mather CA, Qi Z, Wiita AP. False positive cell free DNA screening for microdeletions due to non-pathogenic copy number variants. Prenat Diagn. 2016 Jun; 36(6):584-6.
    View on PubMed
  14. Ori-McKenney KM, McKenney RJ, Huang HH, Li T, Meltzer S, Jan LY, Vale RD, Wiita AP, Jan YN. Phosphorylation of ß-Tubulin by the Down Syndrome Kinase, Minibrain/DYRK1a, Regulates Microtubule Dynamics and Dendrite Morphogenesis. Neuron. 2016 05 04; 90(3):551-63.
    View on PubMed
  15. Julien O, Zhuang M, Wiita AP, O'Donoghue AJ, Knudsen GM, Craik CS, Wells JA. Quantitative MS-based enzymology of caspases reveals distinct protein substrate specificities, hierarchies, and cellular roles. Proc Natl Acad Sci U S A. 2016 Apr 05; 113(14):E2001-10.
    View on PubMed
  16. Wiita AP, Hsu GW, Lu CM, Esensten JH, Wells JA. Circulating proteolytic signatures of chemotherapy-induced cell death in humans discovered by N-terminal labeling. Proc Natl Acad Sci U S A. 2014 May 27; 111(21):7594-9.
    View on PubMed
  17. Carr SA, Abbatiello SE, Ackermann BL, Borchers C, Domon B, Deutsch EW, Grant RP, Hoofnagle AN, Hüttenhain R, Koomen JM, Liebler DC, Liu T, MacLean B, Mani DR, Mansfield E, Neubert H, Paulovich AG, Reiter L, Vitek O, Aebersold R, Anderson L, Bethem R, Blonder J, Boja E, Botelho J, Boyne M, Bradshaw RA, Burlingame AL, Chan D, Keshishian H, Kuhn E, Kinsinger C, Lee JS, Lee SW, Moritz R, Oses-Prieto J, Rifai N, Ritchie J, Rodriguez H, Srinivas PR, Townsend RR, Van Eyk J, Whiteley G, Wiita A, Weintraub S. Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol Cell Proteomics. 2014 Mar; 13(3):907-17.
    View on PubMed
  18. Wiita AP, Seaman JE, Wells JA. Global analysis of cellular proteolysis by selective enzymatic labeling of protein N-termini. Methods Enzymol. 2014; 544:327-58.
    View on PubMed
  19. Wiita AP, Ziv E, Wiita PJ, Urisman A, Julien O, Burlingame AL, Weissman JS, Wells JA. Global cellular response to chemotherapy-induced apoptosis. Elife. 2013 Oct 29; 2:e01236.
    View on PubMed
  20. Wiita AP, Nambiar A. Longitudinal management with crossmatch-compatible platelets for refractory patients: alloimmunization, response to transfusion, and clinical outcomes (CME). Transfusion. 2012 Oct; 52(10):2146-54.
    View on PubMed

Go to UCSF Profiles, powered by CTSI